In tivantinib trials, due to the lack of a convenient and reliable biomarker for detecting c-Met activity (where c-Met phosphorylation represents the most direct detection method), immunohistochemical staining of c-Met overexpression in tumor tissue sections was used as an alternative approach. Here, MET is linked to neoplasm.